Virginia L Stauffer

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285 USA Electronic address
    Schizophr Res 150:434-41. 2013
  2. pmc Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
  3. pmc Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
  4. doi request reprint Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 187:42-8. 2011
  5. pmc Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Virginia L Stauffer
    Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:89. 2010
  6. doi request reprint Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials
    Virginia Stauffer
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 130:11-9. 2011
  7. doi request reprint Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 118:176-82. 2010
  8. pmc Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
  9. doi request reprint Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
    Bonnie A Fijal
    Lilly USA, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:367-71. 2012
  10. ncbi request reprint Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 102:230-40. 2008

Detail Information

Publications29

  1. ncbi request reprint Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285 USA Electronic address
    Schizophr Res 150:434-41. 2013
    ..This study found no benefit of adjunctive LY2140023 versus PBO for negative symptoms in patients with schizophrenia receiving treatment with SOC. LY2140023 was generally well-tolerated in these patients. ..
  2. pmc Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
    ....
  3. pmc Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
    ..To identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic schizophrenia...
  4. doi request reprint Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 187:42-8. 2011
    ..As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis...
  5. pmc Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Virginia L Stauffer
    Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:89. 2010
    ..To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent...
  6. doi request reprint Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials
    Virginia Stauffer
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 130:11-9. 2011
    ..Most patients had modest and sustained improvements during atypical antipsychotic treatment, regardless of their baseline illness severity, representing a partial response to currently available treatments...
  7. doi request reprint Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 118:176-82. 2010
    ..In this study, we assessed the effects of early response/non-response to an atypical antipsychotic across multiple outcome measures...
  8. pmc Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
    ....
  9. doi request reprint Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
    Bonnie A Fijal
    Lilly USA, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:367-71. 2012
    ..We examined 6 single nucleotide polymorphisms (SNPs) previously reported to be associated with response to iloperidone therapy for association with response to risperidone therapy...
  10. ncbi request reprint Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 102:230-40. 2008
    ..To test whether early onset of response to antipsychotic medications accurately predicts subsequent response in the treatment of patients with schizophrenia...
  11. doi request reprint Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
    ..This distinction, incorporating an evaluation of the presence of positive, affective, and extrapyramidal symptoms, may therefore not have prognostic implications for the responsiveness of patients' negative symptoms to treatment...
  12. doi request reprint Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46258, USA
    J Clin Psychopharmacol 28:601-7. 2008
    ..Aripiprazole-treated patients had smaller increases in glucose and lipids, but no difference was observed between treatments in the proportion of patients experiencing categorical shifts in these measures...
  13. pmc Predictors of switching antipsychotic medications in the treatment of schizophrenia
    Allen W Nyhuis
    Eli Lilly and Company, Indianapolis, IN USA
    BMC Psychiatry 10:75. 2010
    ..To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia...
  14. ncbi request reprint Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
    Vicki P Hoffmann
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:656-60. 2010
    ..Clinical monitoring is advised throughout treatment for all patients...
  15. doi request reprint Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:286-9. 2010
    ..Early response to antipsychotic treatment discriminated AD from placebo. Reducing placebo-controlled clinical trials from 6 weeks to 2 to 4 weeks was found to be a viable option for efficacy identification in acutely ill patients...
  16. ncbi request reprint Acute dysphoric mania: treatment response to olanzapine versus placebo
    Robert W Baker
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Clin Psychopharmacol 23:132-7. 2003
    ..Additional experience with putative mood stabilizers and atypical agents in mixed mania should include an exploration of their efficacy in treating both manic and depressive mood symptoms...
  17. pmc Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
    Virginia L Stauffer
    Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
    BMC Psychiatry 9:12. 2009
    ..Identification of patient subgroups with different degrees of susceptibility to the effect of weight mitigating agents during olanzapine treatment may aid clinicians in treatment decisions...
  18. ncbi request reprint The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Am Med Dir Assoc 4:189-94. 2003
    ....
  19. pmc Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
    Virginia S Haynes
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 12:222. 2012
    ..This post-hoc analysis of a 3-year study compared the costs of mental health services and functional outcomes between individuals with schizophrenia who met or did not meet cross-sectional symptom remission at study enrollment...
  20. pmc Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
    Haya Ascher-Svanum
    Global Health Outcomes, Eli Lilly and Company, USA
    BMC Psychiatry 11:152. 2011
    ..This study assessed whether early response predicted later response when using a long-acting injection (LAI) antipsychotic...
  21. ncbi request reprint Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania
    Robert W Baker
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Affect Disord 73:147-53. 2003
    ..Presumably, bipolar patients would be at increased risk for this putative adverse event. Therefore, we evaluated the potential of olanzapine to exacerbate symptoms of mania compared to placebo during treatment of bipolar mania...
  22. doi request reprint Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:115-22. 2011
    ..The objective of this study was to compare the cost-effectiveness of olanzapine to aripiprazole in the treatment of schizophrenia from the perspective of public payers in the United States...
  23. ncbi request reprint Bone loss associated with hyperprolactinemia in patients with schizophrenia
    Bruce J Kinon
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN
    Clin Schizophr Relat Psychoses 7:115-23. 2013
    ..The objective of this study was to determine the prevalence of low BMD in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment...
  24. pmc Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
    Xiaomei Peng
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Clinicoecon Outcomes Res 3:79-87. 2011
    ....
  25. ncbi request reprint All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 27:252-8. 2007
    ..This integrated analysis compared the likelihood of discontinuation from olanzapine treatment versus other antipsychotics among patients with schizophrenia...
  26. pmc Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Neuropsychiatr Dis Treat 8:113-8. 2012
    ..Current findings are consistent with physicians' stated reasons for switching versus augmenting antipsychotics in the treatment of schizophrenia. Confirmation of these findings requires further research...
  27. pmc Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
    Lei Chen
    Eli Lilly and Company, Indianapolis, IN, USA
    Neuropsychiatr Dis Treat 9:815-22. 2013
    ..This study identified subgroups of patients with schizophrenia who differed on their movement disorder profile and compared their treatment outcomes...
  28. ncbi request reprint Dose response and atypical antipsychotics in schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    CNS Drugs 18:597-616. 2004
    ..Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events. Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics...
  29. ncbi request reprint The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania
    Robert W Baker
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bipolar Disord 4:43-9. 2002
    ..In this secondary analysis of a placebo-controlled trial demonstrating olanzapine's efficacy for acute mania, we explore whether its usefulness extends to those patients with a history of poor response to other mood stabilizers...